CompletedNot Applicable

Cardiac Sarcoidosis and FDG-PET

Japan20 participantsStarted 2004-03

Plain-language summary

Sarcoidosis is a multi-systemic inflammatory disorder of unknown cause characterized by the formation of non-caseating granulomas in involved organs. Its cardiac involvement may be potentially fatal. Although endomyocardial biopsy is required for deﬁnitive diagnosis of cardiac sarcoidosis, it is invasive and lacks sensitivity. The specific diagnostic tool for cardiac sarcoidosis is far from satisfactory. Recent studies have revealed that FDG-PET with under fasting conditions is a useful method for identiﬁcation of cardiac sarcoidosis patients. However, to our knowledge, no investigations have been published with regard to FDG quantification for the diagnosis and management of cardiac sarcoidosis by PET.

Who can participate

Age range35 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects between the ages of 35 and 85 years * Subjects with systemic sarcoidosis * Subjects with idiopathic sarcoidosis Exclusion Criteria: * Subjects with active inflammatory diseases not related to sarcoidosis * Subjects with coronary artery disease and primary valvular heart diseases * Subjects with uncontrolled diabetes mellitus or insulin treatment * Subjects with use of the corticosteroid * Subjects with systemic disorders such as active inflammatory, liver, renal, hematopoietic, and malignant disease

What they're measuring

Usefulness of Fasting FDG-PET for Diagnosis and Management of Cardiac Sarcoidosis

Timeframe: Baseline and at 1, 3, 6, 12 months after the initial FDG-PET

Trial details

NCT IDNCT00958087

SponsorKurume University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2010-03

View on ClinicalTrials.gov More Sarcoidosis trials